Key Takeaways BTSG posted 33% growth in infusion and specialty pharmacy in Q1, outpacing OPCH's 16% revenue increase. OPCH is boosting margins via AI tools from Palantir and RPA to enhance efficiency and cost control. BTSG's 2025 EPS is projected to rise 82.1%, more than double OPCH's estimated 36.6% improvement.As the healthcare industry continues shifting toward decentralized, patient-centric care models, home infusion and specialty pharmacy services are gradually becoming key battlegrounds for growth. ...